biostudies-literatureRao VSNHLBI NIH HHSNational Institutes of HealthAstraZeneca340-346https://www.ebi.ac.uk/biostudies/studies/S-EPMC10947725biostudies-literatureUnknown30(2)<h4>Background and objectives</h4>Approaches to distinguishing pathological cardiorenal dysfunction in heart failure (HF) from functional/hemodynamically mediated changes in serum creatinine are needed. We investigated urine galectin-3 as a candidate biomarker of renal fibrosis and a prognostic indicator of cardiorenal dysfunction phenotypes.<h4>Methods</h4>We measured urine galectin-3 in 2 contemporary HF cohorts: the Yale Transitional Care Clinic (YTCC) cohort (n = 132) and the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial (n = 434). We assessed the association of urine galectin-3 with all-cause mortality in both cohorts and the association with an established marker of renal tissue fibrosis, urinary amino-terminal propeptide of type Journal of cardiac failureAssociation of Urine Galectin-3 With Cardiorenal Outcomes in Patients With Heart Failure.PMC10947725R21 HL143092K23 HL114868L30 HL115790R01HL128973R01 HL128973L30HL115790R01HL148354K23HL114868R01HL139629R01 HL148354R21HL143092R01 HL139629Cox ZLIvey-Miranda JBMoreno-Villagomez JRao VSTestani JMfalseAssociation of Urine Galectin-3 With Cardiorenal Outcomes in Patients With Heart Failure.<h4>Background and objectives</h4>Approaches to distinguishing pathological cardiorenal dysfunction in heart failure (HF) from functional/hemodynamically mediated changes in serum creatinine are needed. We investigated urine galectin-3 as a candidate biomarker of renal fibrosis and a prognostic indicator of cardiorenal dysfunction phenotypes.<h4>Methods</h4>We measured urine galectin-3 in 2 contemporary HF cohorts: the Yale Transitional Care Clinic (YTCC) cohort (n = 132) and the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial (n = 434). We assessed the association of urine galectin-3 with all-cause mortality in both cohorts and the association with an established marker of renal tissue fibrosis, urinary amino-terminal propeptide of type 2024-01-01T00:00:00Z2024 Feb2025-04-05T10:19:40.313Z2025-04-05T10:19:40.313ZS-EPMC109477253730124810.1016/j.cardfail.2023.05.018